CompletedPhase 2NCT00390325
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Studying Multiple endocrine neoplasia type 2A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Bhavana Konda, M.DOhio State University Comprehensive Cancer Center
- Intervention
- Sorafenib Tosylate(drug)
- Enrollment
- 21 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2022
Study locations (3)
- Washington University School of Medicine, St Louis, Missouri, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00390325 on ClinicalTrials.gov